Auris Medical -Model AM-125 -Therapeutics for Inner Ear Disorders
FromAuris Medical AG
AM-125 for the treatment of vertigo is expected to complete its Phase 2 TRAVERS trial in Q2 2022 and to move into Phase 3 in Q4 2022. Keyzilen® (AM-101) for the treatment of acute inner ear tinnitus and Sonsuvi® (AM-111) for the treatment of acute inner ear hearing loss have both been evaluated in Phase 3 trials, but will require further clinical testing.
Most popular related searches
Preclinical and clinical evidence
Superior bioavailability
Intranasal delivery of betahistine results in 5 to 29 times higher plasma exposure compared to standard oral administration.
Accelerated and improved balance function
Dose dependent improvement in balance for neurosurgery patients suffering from acute vertigo
Current clinical investigations
For participation in a clinical investigation with AM-125, please check the following information resource: